Corrections: The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study (The Lancet Neurology (2018) 17(5) (434–444)(S147444221830053X)(10.1016/S1474-4422(18)30053-X));The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study

The Lancet Neurology

Volumn 17, Issue 5, 2018, Pages 434-444

  van der Lee, Sven J ^a   Wolters, Frank J ^a   Ikram, M Kamran ^a   Hofman, Albert ^a,b   Ikram, M Arfan ^a   Amin, Najaf ^a   van Duijn, Cornelia M ^a,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; APOE PROTEIN, HUMAN;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; ATTRIBUTABLE RISK; COHORT ANALYSIS; DEMENTIA; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HIGH RISK POPULATION; HOMOZYGOTE; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; VERY ELDERLY; GENETICS; MIDDLE AGED; NETHERLANDS; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEINS E; COHORT STUDIES; DEMENTIA; FEMALE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; RISK ASSESSMENT;

EID: 85044163802     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(18)30163-7     Document Type: Erratum

References (53)

1. Gatz, M, Reynolds, CA, Fratiglioni, L, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 63 (2006), 168–174.
2. Saunders, AM, Strittmatter, WJ, Schmechel, D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43 (1993), 1467–1472.
3. Farrer, LA, Cupples, LA, Haines, JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278 (1997), 1349–1356.
4. Genin, E, Hannequin, D, Wallon, D, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 16 (2011), 903–907.
5. Seshadri, S, Drachman, DA, Lippa, CF, Apolipoprotein E epsilon 4 allele and the lifetime risk of Alzheimer's disease. What physicians know, and what they should know. Arch Neurol 52 (1995), 1074–1079.
6. Moulder, KL, Snider, BJ, Mills, SL, et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res Ther, 5, 2013, 48.
7. Reiman, EM, Langbaum, JB, Fleisher, AS, et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 26:suppl 3 (2011), 321–329.
8. Jack, CR Jr, Knopman, DS, Jagust, WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12 (2013), 207–216.
9. Lambert, JC, Heath, S, Even, G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41 (2009), 1094–1099.
10. Hollingworth, P, Harold, D, Sims, R, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 43 (2011), 429–435.
11. Lambert, JC, Ibrahim-Verbaas, CA, Harold, D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 45 (2013), 1452–1458.
12. Guerreiro, R, Wojtas, A, Bras, J, et al. TREM2 variants in Alzheimer's disease. N Engl J Med 368 (2013), 117–127.
13. Naj, AC, Jun, G, Beecham, GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 43 (2011), 436–441.
14. Desikan, RS, Schork, AJ, Wang, Y, et al. Polygenic overlap between C-reactive protein, plasma lipids, and Alzheimer disease. Circulation 131 (2015), 2061–2069.
15. Jun, G, Ibrahim-Verbaas, CA, Vronskaya, M, et al. A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry 21 (2016), 108–117.
16. Seshadri, S, Fitzpatrick, AL, Ikram, MA, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303 (2010), 1832–1840.
17. Jonsson, T, Stefansson, H, Steinberg, S, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 368 (2013), 107–116.
18. Ruiz, A, Dols-Icardo, O, Bullido, MJ, et al. Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia. Neurobiol Aging 35 (2014), 444.e1–444.e4.
19. Harold, D, Abraham, R, Hollingworth, P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41 (2009), 1088–1093.
20. Sleegers, K, Bettens, K, De Roeck, A, et al. A 22-single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid Abeta42. Alzheimers Dement 11 (2015), 1452–1460.
21. Chouraki, V, Reitz, C, Maury, F, et al. Evaluation of a genetic risk score to improve risk prediction for Alzheimer's disease. J Alzheimers Dis 53 (2016), 921–932.
22. Escott-Price, V, Sims, R, Bannister, C, et al. Common polygenic variation enhances risk prediction for Alzheimer's disease. Brain 138 (2015), 3673–3684.
23. Desikan, RS, Fan, CC, Wang, Y, et al. Genetic assessment of age-associated Alzheimer disease risk: development and validation of a polygenic hazard score. PLoS Med, 14, 2017, e1002258.
24. Rodriguez-Rodriguez, E, Sanchez-Juan, P, Vazquez-Higuera, JL, et al. Genetic risk score predicting accelerated progression from mild cognitive impairment to Alzheimer's disease. J Neural Transm (Vienna) 120 (2013), 807–812.
25. Adams, HH, de Bruijn, RF, Hofman, A, et al. Genetic risk of neurodegenerative diseases is associated with mild cognitive impairment and conversion to dementia. Alzheimers Dement 11 (2015), 1277–1285.
26. Lacour, A, Espinosa, A, Louwersheimer, E, et al. Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment. Mol Psychiatry 22 (2017), 153–160.
27. Seshadri, S, Wolf, PA, Beiser, A, et al. Lifetime risk of dementia and Alzheimer's disease. The impact of mortality on risk estimates in the Framingham Study. Neurology 49 (1997), 1498–1504.
28. Wolters, FJ, van der Lee, SJ, Koudstaal, PJ, et al. Parental family history of dementia in relation to subclinical brain disease and dementia risk. Neurology 88 (2017), 1642–1649.
29. Ikram, MA, Brusselle, GGO, Murad, SD, et al. The Rotterdam Study: 2018 update on objectives, design and main results. Eur J Epidemiol 32 (2017), 807–850.
30. de Bruijn, RFAG, Bos, MJ, Portegies, MLP, et al. The potential for prevention of dementia across two decades: the prospective, population-based Rotterdam Study. BMC Med, 13, 2015, 132.
31. Schrijvers, EM, Verhaaren, BF, Koudstaal, PJ, Hofman, A, Ikram, MA, Breteler, MM, Is dementia incidence declining?: Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology 78 (2012), 1456–1463.
32. van Leeuwen, EM, Kanterakis, A, Deelen, P, et al. Population-specific genotype imputations using minimac or IMPUTE2. Nat Protoc 10 (2015), 1285–1296.
33. McCarthy Group Tools. HRC or 1000G Imputation preparation and checking. http://www.well.ox.ac.uk/∼wrayner/tools/#Checking (accessed Jan 10, 2016).
34. McCarthy, S, Das, S, Kretzschmar, W, et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat Genet 48 (2016), 1279–1283.
35. Allignol, A, Schumacher, M, Beyersmann, J, Empirical transition matrix of multi-state models: the etm package. J Stat Softw 38 (2011), 1–15.
36. Meister, R, Schaefer, C, Statistical methods for estimating the probability of spontaneous abortion in observational studies—analyzing pregnancies exposed to coumarin derivatives. Reprod Toxicol 26 (2008), 31–35.
37. Kaplan, EL, Meier, P, Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958), 457–481.
38. Tsai, WY, Jewell, NP, Wang, MC, A Note on the product-limit estimator under right censoring and left truncation. Biometrika 74 (1987), 883–886.
39. Alzheimer's Association. 2016 Alzheimer's disease facts and figures. Alzheimers Dement 12 (2016), 459–509.
40. Seshadri, S, Wolf, PA, Lifetime risk of stroke and dementia: current concepts, and estimates from the Framingham Study. Lancet Neurol 6 (2007), 1106–1114.
41. McDaid, AF, Joshi, PK, Porcu, E, et al. Bayesian association scan reveals loci associated with human lifespan and linked biomarkers. Nat Commun, 8, 2017, 15842.
42. Galea, S, Tracy, M, Participation rates in epidemiologic studies. Ann Epidemiol 17 (2007), 643–653.
43. Marden, JR, Mayeda, ER, Walter, S, et al. Using an Alzheimer disease polygenic risk score to predict memory decline in black and white Americans over 14 years of follow-up. Alzheimer Dis Assoc Disord 30 (2016), 195–202.
44. International Genomics of Alzheimer's Disease Consortium (IGAP). Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimers Dement 11 (2015), 658–671.
45. Liu, CC, Kanekiyo, T, Xu, H, Bu, G, Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9 (2013), 106–118.
46. Myers, RH, Schaefer, EJ, Wilson, PW, et al. Apolipoprotein E epsilon4 association with dementia in a population-based study: the Framingham study. Neurology 46 (1996), 673–677.
47. Bickeboller, H, Campion, D, Brice, A, et al. Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex. Am J Hum Genet 60 (1997), 439–446.
48. Cupples, LA, Farrer, LA, Sadovnick, AD, Relkin, N, Whitehouse, P, Green, RC, Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. Genet Med 6 (2004), 192–196.
49. Seshadri, S, Beiser, A, Kelly-Hayes, M, et al. The lifetime risk of stroke: estimates from the Framingham Study. Stroke 37 (2006), 345–350.
50. Bras, J, Guerreiro, R, Darwent, L, et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet 23 (2014), 6139–6146.
51. Khan, TA, Shah, T, Prieto, D, et al. Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: systematic review and meta-analysis of 14,015 stroke cases and pooled analysis of primary biomarker data from up to 60,883 individuals. Int J Epidemiol 42 (2013), 475–492.
52. Guerreiro, R, Escott-Price, V, Darwent, L, et al. Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. Neurobiol Aging 38 (2016), 214.e7–214.e10.
53. Naj, AC, Jun, G, Reitz, C, et al. Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study. JAMA Neurol 71 (2014), 1394–1404.